Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 18/20 | 0.67 |
| ▸ | PPARA | Q07869 | 17/20 | 0.67 |
| ▸ | PPARD | Q03181 | 3/20 | 0.67 |
| ▸ | PGR | P06401 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | PDE4A | P27815 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5015073 | 1.00 | PPARG (0.67) | PPARGPPARAPPARDPGRADORA3 | |
| SCHEMBL5015518 | 1.00 | PPARG (0.67) | PPARGPPARAPPARDPGRADORA3 | |
| SCHEMBL5015605 | 0.93 | PPARG (0.65) | PPARGPPARAPPARDPGRADORA3 | |
| SCHEMBL14010682 | 0.93 | PPARG (0.56) | PPARGPPARAPPARD | |
| SCHEMBL5015569 | 0.92 | PPARA (0.55) | PPARGPPARAPPARD | |
| SCHEMBL5014125 | 0.90 | PPARG (0.58) | PPARGPPARAPPARDPGRADORA3 | |
| SCHEMBL5015601 | 0.89 | PPARG (0.57) | PPARGPPARAPPARDPGRADORA3 | |
| SCHEMBL5015608 | 0.89 | PPARA (0.57) | PPARGPPARAPPARDPGRADORA3 | |
| SCHEMBL5488110 | 0.88 | SMN1; SMN2 (0.49) | PPARGPPARAPPARD | |
| SCHEMBL5484833 | 0.88 | SMN1; SMN2 (0.49) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456293-B2 | Substituted carboxylic acid derivatives for the treatment of diabetes and lipid disorders, their preparation and use | SK HOLDING CO., LTD (KR) | 2008-11-25 | — | — | US | disclosed |
| US-7456293-B2 | Substituted carboxylic acid derivatives for the treatment of diabetes and lipid disorders, their preparation and use | SK HOLDING CO., LTD (KR) | 2008-11-25 | — | — | US | disclosed |
| US-7456293-B2 | Substituted carboxylic acid derivatives for the treatment of diabetes and lipid disorders, their preparation and use | SK HOLDING CO., LTD (KR) | 2008-11-25 | — | — | US | disclosed |
| US-20060281802-A1 | Substituted carboxylic acid derivatives for the treatment of diabetes and lipid disorders, their preparation and use | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281802-A1 | Substituted carboxylic acid derivatives for the treatment of diabetes and lipid disorders, their preparation and use | SLC5A1, CPT1A, GPR119 | PPARG 166/4885PPARA 174/4885PPARD 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.